DDInter1055 DDInter725
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Used in treatment of iron deficiency anemia.
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ferrous fumarate
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ferrous fumarate
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolic acid
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ferrous fumarate
Levofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolic acid
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ferrous fumarate
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolic acid
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ferrous fumarate
Levofloxacin {u} (Compound) downregulates {v} (Gene) PTPN1
PTPN1 {u} (Gene) is upregulated by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ferrous fumarate
Levofloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Gemifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ferrous fumarate
Levofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ferrous fumarate
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ferrous fumarate
Levofloxacin {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ferrous fumarate
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Levofloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Levofloxacin (Compound) downregulates PTPN1 (Gene) and PTPN1 (Gene) is upregulated by Mycophenolic acid (Compound) and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Levofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Levofloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Levofloxacin (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Mycophenolic acid (Compound) and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate